Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung

Completed · Phase 1/Phase 2

Conditions studied: Osteosarcoma Metastatic

In brief

Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma metastatic to the lung.

Key facts

Study ID

NCT00102531

Run by

Insmed Incorporated

People needed

19

Starts

2005-01-12

Expected to finish

2008-03-17

Last updated by the study team

2017-08-01

Who can join

Age: 13 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven, Progressive or recurrent high grade osteosarcoma metastatic to the lung
• Patients with histologically proven, fully malignant high-grade osteosarcoma of bone
• Measureable pulmonary metastases
• Less than grade 3 neuropathies, insignificant decreases in cardiac or auditory function
• ECOG performance status of 0, 1 or 2
• FEV1 of 50% or greater of predicted value
• FEV1/FVC ratio of 65% or greater
• Serum creatinine of ≤ 1.5 mg/dl
• Total bilirubin ≤ 1.5mg/dl and SGOT or SGPT < 2.5 times upper normal limit
• ANC of ≥ 1,000/mm3 and platelet count of ≥ 100,000/mm3

You may not qualify if…

• Grade 3 or higher painful neuropathy persisting after a prior platinum containing regimen
• Patients who are pregnant or are of childbearing potential and not using methods to avoid pregnancy
• Concurrent systemic chemotherapy
• Greater than Grade 2 pulmonary toxicity
• Pulmonary atelectasis
• Reactive airway disease which has resulted in hospitalization within the last year or which requires daily treatment with bronchodilator therapy
• Concurrent serious infections
• Unstable or serious concurrent medical condition
• Recent major surgery or thoracic radiation therapy or chemotherapy
• Significant pulmonary fibrosis secondary to prior radiation
• Major ventilatory distribution abnormalities
• Osteosarcoma secondary to radiation or premalignant conditions
• History of prior malignancy
• Low grade osteosarcoma, parosteal or periosteal sarcoma

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• The Albert Einstein College of Medicine Montefiore Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.